Tag: medicines

Virtual webinar on June 23, 2025 at 8:00 am ET

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

PARIS, FRANCE, 20 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumors who have progressed following at least one prior systemic therapy other than somatostatin analogues. This recommendation is based on results from the CABINET Phase III trial presented at the European Society of Medical Oncology (ESMO) Congress 2024 and published in the New England Journal of Medicine.^3,4 A final decision on the approval in the European Union is expected in the coming months.

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

PITTSBURGH, June 19, 2025 (GLOBE NEWSWIRE) -- Episource LLC (“Episource”) recently announced a data breach, which compromised the personal information of approximately five million individuals. The information potentially impacted in the data breach includes individuals’ names, addresses, email addresses, phone numbers, insurance plan information, Medicaid IDs, Social Security numbers, and medical record information, including diagnoses, medicines, test results, images, treatments.¹